Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q3 2014 · 10-Q
Revenue$434.04K$434.04K+56.5% vs Q3 2013 Net Income-$383.88K-$383.88KN/M vs Q3 2013 EPS Diluted$0.00$0.00— vs Q3 2013 Gross Profit$349,663+26.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$285,459N/M Margins · derivedGross margin80.6%−19.4 pt vs Q3 2013
Net margin-88.4%−41.9 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 10, 2014 · 41 d after period end